Focus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013
|
|
- Blaze Mitchell
- 6 years ago
- Views:
Transcription
1 Focus on FH (Familial Hypercholesterolemia) Joshua W. Knowles, MD PhD for PCNA May, 2013
2 Conflicts CMO for The FH Foundation
3 Pre-talk quiz
4 What is cascade screening? 1. screening all family members 2. screening potentially affected family members 3. screening kids 69% 28% 4%
5 What is the goal LDL cholesterol for an FH patient? < 50% of pre-treatment LDL 100mg/dl 130mg/dl 60% 19% 22%
6 Mutations in 3 genes cause FH, what gene is not an FH gene? APOB LDLR PCSK9 LPA 12% 10% 57% 21%
7 DIAGNOSIS Familial Hypercholesterolemia
8 Can t find FH if you don t look! For adults > 20 yo: Suspect FH if LDL 190 mg/dl Average LDL in adult FH patients ~ 220 mg/dl FH more likely if FHx of premature coronary disease Look for physical exam findings of FH Xanthomas, xanthelasma, corneal arcus (< 45 yo) For children suspect FH if LDL 160 mg/dl
9
10 Formal Diagnostic criteria Three validated criteria MEDPED Dutch Lipid Clinic Network Simon Broome Register Once FH proband identified lower cut-offs for LDL should be used
11 Slide from MEDPED, courtesy of Dr. Hopkins
12 Dutch Lipid Clinic Network criteria Haase and Goldberg, 2012 Curr Op Lipidology WHO report on FH 1999
13 There s an app for that!
14 GENETICS and CASCADE SCREENING Familial Hypercholesterolemia
15 Genetics of FH Autosomal dominant, > 90% penetrance Prevalence heterozygous FH ~ 1 in 500 Homozygous FH ~ 1 in 1 Million Mutations in 3 genes known to cause FH: LDLR (>1000 variants identified, 80-95% of cases) PCSK9 (< 5% of cases): increased activity leads to degradation of LDLR APOB (5-10% of FH in Northern Europe) Decreased binding of ApoB containing particles to LDLR
16 Genetic mutations that cause FH impair LDL clearance FH is typically caused by mutations in LDLR, Apo B, PCSK9 Apo B: acts as ligand-binding LDL particle to receptor 1:1000 or 10% of FH cases Circulation Liver cell LDL receptor (LDLR): on hepatocyte, binds to Apo B on LDL particle, inducing endocytosis of LDL 1:500 or >85% of mutations PCSK9 enzyme: degrades LDL receptors 1:2500 or <5% of FH cases LDLRAP1 = low-density lipoprotein receptor adaptor protein 1. Image reproduced from: Department of Life Sciences and Institute and Institute of Genome Sciences Web site. Published June 11, Accessed January 19, De Castro-Oros I, et al. Appl Clin Genet. 2010;3: Rader DJ, et al. J Clin Invest. 2003;111: Slide courtesy of NSGC 3. Hopkins PN, et al. J Clin Lipol. 2011;5(3 suppl):s9-s17.
17 Genetic testing is not: Or
18 Genetic testing for FH In the US, the FH usually diagnosed on clinical grounds. Genetic testing can be used in cases where the diagnosis is unclear. Genetic testing is widely used in many countries. Testing generally involves sequencing 3 genes (LDLR, APOB and PCSK9). The yield on genetic testing is ~85% in definite FH cases and ~50% in possible FH. It is probable that this method will be used more widely. May be particularly useful for cascade screening.
19 Whether or not genetic testing is used cascade screening is a MUST! UK screening algorithm NICE guidelines (UK), FH 2008 (Natl Inst. Health and Clin. Ex.)
20 Every family tree is a Family Pre-treatment lipids: TC 327 LDL 265 HDL 51 TG 55
21 If no genetic test results you must use less stringent LDL levels in screening relatives!
22 Dutch experience National lipid and genetic cascade screening program for FH (prevalence 1:400) Set up 1994 So far identified over FH patients First 5 years screened 5442 relatives of 237 FH patients and identified 2039 carriers. Initially only 39% were on meds 2 years after molecular diagnosis 85% on meds Cascade genetic testing is cost effective $8700 per life year gained Work from JJP Kastelein s group Leren, T et al. Comm Genetics 2008
23 CDC has classified FH as a Tier 1 condition FH is a Winnable battle
24 FH Foundation and Registry
25 MANAGEMENT Familial Hypercholesterolemia
26 Management Diet/lifestyle changes important Reduce saturated fat High soluble fiber: 10-20g/day Consider dietician referral Statins are the mainstay of therapy Many will require 2 or more drugs Treat other risk factors (HTN, smoking) DO NOT USE standard risk assessment tools (like Framingham) to estimate risk
27 Goals of therapy FH patients are considered high risk based on NCEP, AHA/ACC, NLA guidelines Rule of thumb to try to cut LDL by 50% Ultimate goal LDL < 100 or even < 70 mg/dl Unlike garden variety HLD non-statin agents like ezetimibe are standard of care Proper therapy can reduce risk of CHD by 80% NCEP ATP Guidelines, Circ 2002.
28 In properly treated FH patients, mortality is similar to the general population Data starting Jan 1, 1990 Just after first statin introduced in the Netherlands Versmissen, J et al. BMJ. 2008
29 Many FH patients cannot get to goal LDL levels with current therapies HeFH Only ~ 20% of patients achieve LDL < 100 mg/dl Only ~ 40% of patients achieve LDL < 130 mg/dl Statin intolerance is a big problem. In clinical practice ~ 10-15% of FH patients are statin intolerant or have significant side effects Majority of HoFH do not have a healthy LDL. Most have disease progression even with apheresis Pijlman et al. Atherosclerosis. 2009
30 LDL apheresis is indicated for HoFH and sometimes for HeFH Apheresis lowers LDL ~80% acutely and ~40% chronically (weekly or biweekly) Indicated if LDL not at goal after 6 mo of diet/meds: HoFH with LDL 300mg/dl HeFH with LDL 300mg/dl plus 0-1 risk factors HeFH with LDL 200mg/dl and 2+ high risk factors HeFH with LDL 160mg/dl very high risk (known CAD) Limited by availability, cost and duration of therapy Usually require weekly sessions, offered ~ 40 centers in US Raal and Santos. Atherosclerosis Horton. J. Lipid. Res. 2009
31 Drug therapies PCSK9 inhibitors Slide adapted from Dan Rader
32 Class Statins Bile Acid Sequestrants Cholesterol Absorption Inhibitor Stanol esters Nicotinic acid LDL apheresis Primary Mechanism of Action (Effects on Lipoprotein Metabolism 1 ) Inhibition of HMG-CoA Reductase ( LDLC clearance via LDL receptors) Bile acid re-absorption ( LDLC clearance via LDL receptors) Intestinal Cholesterol absorption via NPC1L1 ( LDLC clearance via LDL receptors) Intestinal Cholesterol absorption ( LDLC clearance via LDL receptors) Inhibits lipolysis in adipocytes ( VLDL/LDL synthesis; HDLC clearance) Removal of ApoB containing particles ( VLDL, IDL, LDL, RLP) % Reduction in LDL-C HeFH HoFH >35% 2 Up to 28% 3 Usually 10-20% 15% <10% 15% <10% 10% <10% 20% <10% ~40% 4 (up to 75% acutely 5 ) Lomitapide Inhibition of MTP Not indicated ~ 40% Mipomersen ApoB antisense Not indicated ~ 25% Table adapted from Rader DJ, et al. J Clin Invest. 2003;111(12): Stone, NJ and Blum, CB. (2005) Management of Lipids in Clinical Practice. 5 th Ed. 2. Kastelein JJ, et al. N Engl J Med. 2008;358(14); Raal FJ, et al. Atherosclerosis. 2000;150(2): Ito MK, et al. J Clin Lipidol. 2011;5(3 Suppl):S38-S Gordon BR, et al. Am J of Card. 1998;81(4):
33 29 HoFH patients Avg LDL 340mg/dl
34 Mipomersen Antisense to ApoB. Weekly injection Lowers LDL and Lp(a) Raal et al. Lancet 2010
35 Summary FH is a serious cause of morbidity and mortality Prevalence HeFH 1:500 Vastly under diagnosed and treated Suspect FH if untreated LDL > 190 in an adult Take additional family history, look for xanthomas With proper therapy, morbidity is similar to general population Most will require 2 or more drugs Imperative to initiate cascade screening in family members
36 Post-test quiz What is cascade screening? Screening relatives of affected individuals What is the goal LDL for an FH patient? Half or < 100 mg/dl Mutations in 3 genes cause FH, what are they? LRLR, APOB, PCSK9
REPATHA (PCSK9 INHIBITORS)
REPATHA (PCSK9 INHIBITS) Indications: PCSK9 Inhibitors are indicated for treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease as
More informationNew Drugs for Lipid Management
New Drugs for Lipid Management John Larry, MD Assistant Professor-Clinical Section Chief, OSU East Cardiovascular Medicine Department of Internal Medicine Division of Cardiovascular Medicine The Ohio State
More informationNew Drugs for Lipid Management
New Drugs for Lipid Management John Larry, MD Assistant Professor-Clinical Section Chief, OSU East Cardiovascular Medicine Department of Internal Medicine Division of Cardiovascular Medicine The Ohio State
More informationEvaluating Residual Risk and Long-term Management of the Young CHD Patient. The Arterial Wall
Evaluating Residual Risk and Long-term Management of the Young CHD Patient Patrick M Moriarty, M.D., Professor of Medicine Director of Clinical Pharmacology, Atherosclerosis and Lipoprotein-apheresis Center
More informationADMINISTRATIVE POLICY AND PROCEDURE
ADMINISTRATIVE POLICY PROCEDURE Policy #: Subject: PCSK9 INHIBITS (ex: Repatha) Section: Care Management Effective Date: January 1, 2015 Revision Date(s): NA Review Date(s): NA Responsible Parties: Patryce
More informationIdentification and management of familial hypercholesterolaemia (FH) - An overview
Identification and management of familial hypercholesterolaemia (FH) - An overview National Collaborating Centre for Primary Care and Royal College of General Practitioners NICE Guideline CG 71 (August
More informationDIAGNOSIS AND TREATMENT OF FH CHILDREN. O. GUARDAMAGNA Dipartimento di Scienze della Sanità Pubblica e Pediatriche UNIVERSITA DI TORINO
DIAGNOSIS AND TREATMENT OF FH CHILDREN O. GUARDAMAGNA Dipartimento di Scienze della Sanità Pubblica e Pediatriche UNIVERSITA DI TORINO DISCLOSURES Kowa MSD Pfizer Astrazeneca Synageva/Alexion OUTLINE Background
More informationFamilial hypercholesterolaemia
Familial hypercholesterolaemia Jaimini Cegla MRCP FRCPath PhD Consultant in Chemical Pathology and Metabolic Medicine Hammersmith Hospital Lipid Clinic 20 April 2017 An unrecognised, potentially fatal,
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationPharmacy Management Drug Policy
SUBJECT: ; Praluent (alirocumab), Repatha (evolocumab) POLICY NUMBER: Pharmacy-61 EFFECTIVE DATE: 8/15 LAST REVIEW DATE: 9/22/2017 If the member s subscriber contract excludes coverage for a specific service
More informationInhibition of PCSK9: The Birth of a New Therapy
Inhibition of PCSK9: The Birth of a New Therapy Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Disclosures Dr. Kastelein
More informationThe role of mipomersen therapy in the treatment of familial hypercholesterolemia
Reviews: Clinical Trial Outcomes The role of mipomersen therapy in the treatment of familial hypercholesterolemia Clin. Invest. (2012) 2(10), 1033 1037 Familial hypercholesterolemia (FH) is a genetic disorder
More informationClinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPA.171 Effective Date:
Clinical Policy: (Kynamro) Reference Number: ERX.SPA.171 Effective Date: 01.11.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:
Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationClinical Policy: Mipomersen (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017
Clinical Policy: (Kynamro) Reference Number: ERX.SPMN.186 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationLipid Metabolism in Familial Hypercholesterolemia
Lipid Metabolism in Familial Hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis
More informationJuxtapid (lomitapide)
Juxtapid (lomitapide) Policy Number: 5.01.599 Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Juxtapid
More informationFamilial Hypercholeterolaemia
Familial Hypercholeterolaemia Is it all about statins? Gerald F Watts DSc PhD MD FRACP FRCP Professor and Head, Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital School of Medicine,
More informationDistinguishing FH from non-fh: Right therapy, right patient, right time. Joshua W. Knowles, MD, PhD Stanford and the FH Foundation
Distinguishing FH from non-fh: Right therapy, right patient, right time Joshua W. Knowles, MD, PhD Stanford and the FH Foundation Disclosures Role as CMA of the FH Foundation is not compensated. www.thefhfoundation.org
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationUpdate on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics
Review Article Endocrinol Metab 2017;32:36-40 https://doi.org/10.3803/enm.2017.32.1.36 pissn 2093-596X eissn 2093-5978 Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel
More informationFamilial Hypercholesterolemia What a cardiologist should know
Institut für Klinische Chemie Arnold von Eckardstein Familial Hypercholesterolemia What a cardiologist should know Etiology of Hypercholesterolemia monogenic: (rare): e.g. familial hypercholesterolemia
More informationPresenter Disclosure Information
1:45 2:45pm Lipid Management: A Primary Care Perspective Presenter Disclosure Information The following relationships exist related to this presentation: Richard F. Wright, MD, FACC, has no financial relationships
More informationRequest for Prior Authorization for PCSK9 inhibitor therapy Website Form Submit request via: Fax
Request for Prior Authorization for PCSK9 inhibitor therapy Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 PCSK9 is a protein that reduces the hepatic removal of low-density
More informationGenetic considerations in the treatment of familial hypercholesterolemia
Clinical Lipidology ISSN: 1758-4299 (Print) 1758-4302 (Online) Journal homepage: https://www.tandfonline.com/loi/tlip20 Genetic considerations in the treatment of familial hypercholesterolemia Ann M Moyer
More informationCascade Screening for FH: the U.S. experience
Cascade Screening for FH: the U.S. experience Paul N. Hopkins, MD, MSPH Professor of Internal Medicine Cardiovascular Genetics University of Utah Disclosures Consultant Genzyme, Amgen, Regeneron Research
More informationThe Addition of Ezetimibe to Statin therapy in. Patients with Homozygous Familial. Hypercholesterolaemia
The Addition of Ezetimibe to Statin therapy in Patients with Homozygous Familial Hypercholesterolaemia Submitted in fulfilment with the requirements for the degree Master in Medicine (MMed) Dr Adriano
More informationProprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary
Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization
More informationThis policy addresses the use of Juxtapid (lomitapide) for the treatment of treatment of homozygous familial hypercholesterolemia.
Subject: Juxtapid (lomitapide) Original Effective Date: 10/30/2013 Policy Number: MCP-155 Revision Date(s): Review Date(s): 12/16/15; 6/15/2016; 3/21/2017 DISCLAIMER This Medical Policy is intended to
More informationUNIVERSITA DI PISA CHIMICA E TECNOLOGIE FARMACEUTICHE FAMILIAL HYPERCHOLESTEROLEMIA DIPARTIMENTO DI FARMACIA GENETIC CAUSES AND THERAPY
UNIVERSITA DI PISA DIPARTIMENTO DI FARMACIA CHIMICA E TECNOLOGIE FARMACEUTICHE CORSO DI BASI BIOCHIMICHE DELL AZIONE DEI FARMACI FAMILIAL HYPERCHOLESTEROLEMIA GENETIC CAUSES AND THERAPY ERIKA ROSARIA PACCIOLLA
More informationCase Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic
Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationCost effectiveness of cascade testing for FH:
Cost effectiveness of cascade testing for FH: Background In 2008, NICE published evidence-based guidelines for identification and management of FH Updated 2017 Recommended all Clinical FH DNA test to confirm
More informationLow-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies
Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies A Consensus Statement from the European Atherosclerosis Society
More informationClinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017
Clinical Policy: (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More informationDrug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Repatha) Reference Number: HIM.PA.SP46 Effective Date: 01.01.18 Last Review Date: Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this
More informationLipid Lowering in Patients at High Risk for Cardiovascular Disease
Lipid Lowering in Patients at High Risk for Cardiovascular Disease Prof. John J.P. Kastelein, MD PhD FESC Dept. of Vascular Medicine Academic Medical Center / University of Amsterdam The Netherlands Novel
More informationPCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia
PCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia Policy Number: Original Effective Date: MM.04.037 08/01/2016 Line(s) of Business: HMO;
More informationPROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) INHIBITORS Praluent (alirocumab) Repatha (evolocumab)
PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) INHIBITORS Praluent (alirocumab) Repatha (evolocumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the
More informationPCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
More informationFamilial Hypercholesterolemia
Familial Hypercholesterolemia Dr.Ramzi Al-Mohammadi Assistant Professor of Medicine Interventional Cardiologist, Advanced HF and Transplant Consultant Classification of Hyperlipedemia Primary hyperlipedemia:
More informationLipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute
Lipid Guidelines Who, What, and How Low Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Disclosures! None Objectives! List factors used in screening for dyslipidemia
More informationHoFH presents with a wide spectrum of LDL-C levels in a genetically confirmed cohort of patients
HoFH presents with a wide spectrum of LDL-C levels in a genetically confirmed cohort of patients Claudia Stefanutti Department of Molecular Medicine, Sapienza University Rome, Italy HoFH, homozygous familial
More informationCardiometabolics in Children or Lipidology for Kids. Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az
Cardiometabolics in Children or Lipidology for Kids Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az No disclosures for this Presentation Death Risk Approximately 40% of
More informationClinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPA.169 Effective Date:
Clinical Policy: (Repatha) Reference Number: ERX.SPA.169 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationTHE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS
THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism
More informationPharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: PCSK9 inhibitors Rx.01.170 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract.
More informationDrug Prior Authorization Guideline PCSK9 Inhibitors -
Drug Prior Authorization Guideline PCSK9 Inhibitors - REPATHA (evolocumab) PRALUENT (alirocumab) PA9911 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below Additional
More informationGuidelines for the Diagnosis and Management of Familial Hypercholesterolaemia
The Cardiac Society of Australia and New Zealand Guidelines for the Diagnosis and Management of Familial Hypercholesterolaemia This guideline was originally developed by David Sullivan, Gerard Watts, Ian
More informationJuxtapid and Kynamro
DRUG POLICY Juxtapid and Kynamro BENEFIT APPLICATION Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions
More informationManaging Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus
Managing Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA Chair, ACC Prevention of Cardiovascular Disease Council and Section The Medical University
More informationJuxtapid. Juxtapid (lomitapide) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Juxtapid Page: 1 of 6 Last Review Date: September 20, 2018 Juxtapid Description Juxtapid (lomitapide)
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Proprotein Convertase Subtilisin/kexin type 9 Page 1 of 22 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Proprotein Convertase Subtilisin/kexin type 9 (PCSK9)
More informationWORKSHOP 1. Management of Patients with Familial Hypercholesterolemia
WORKSHOP 1 Management of Patients with Familial Hypercholesterolemia Tutors: Manal Al-Kindi (Oman)/ Gilles Lambert (France) (Case 1) Zuhier Awan (KSA)/ Raul Santos (Brazil) (Case 2) Khalid Al-Waili (Oman)/
More informationPCSK9 inhibition across a wide spectrum of patients: One size fits all?
PCSK9 inhibition across a wide spectrum of patients: One size fits all? PACE ESC Barcelona 2017 G.K. Hovingh MD PhD MBA dept of vascular medicine Academic Medical Center the Netherlands g.k.hovingh@amc.uva.nl
More informationLDL Apheresis: Familial Hypercholesterolemia
LDL Apheresis: Familial Hypercholesterolemia Joyce L Ross, MSN, CRNP, CCS, FNLA, FPCNA Certified Clinical Specialist, Diplomat ACCL Past President PCNA Immediate Past President National Lipid Association
More informationVery high cholesterol from birth: are target LDL cholesterol levels now achievable with new treatments?
Press release 3 Madrid, May 3 st, 204 82 nd Annual Congress of the European Atherosclerosis Society (EAS) May 3-June 3, Madrid, Spain Very high cholesterol from birth: are target LDL cholesterol levels
More informationSubject: Repatha (evolocumab) Original Effective Date: 09/28/2015. Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17
Subject: Repatha (evolocumab) Original Effective Date: 09/28/2015 Policy Number: MCP-258 Revision Date(s): 5/4/16; 4/17/17 Review Date(s): 5/4/2016, 4/17/2017, 7/10/2018 DISCLAIMER This Medical Policy
More informationFrom Biology to Therapy The biology of PCSK9 in humans Just LDL-cholesterol or more? May 24th. Dr. Gilles Lambert
Dr. Gilles Lambert Associate Professor in Cell Biology University of Nantes Medical School Group Leader, Laboratory of Nutrition and Metabolism, University Hospital of Nantes From Biology to Therapy The
More informationClinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:
Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationANSC/NUTR 618 LIPIDS & LIPID METABOLISM The LDL Receptor, LDL Uptake, and the Free Cholesterol Pool
ANSC/NUTR 618 LIPIDS & LIPID METABOLISM The, LDL Uptake, and the Free Cholesterol Pool I. Michael Brown and Joseph Goldstein A. Studied families with familial hypercholesterolemia. B. Defined the relationship
More informationIf yes, continue to #2. If no, do not approve. DENIAL TEXT: See the initial denial text at the end of the guideline.
Generic Brand HICL GCN Exception/Other LOMITAPIDE JUXTAPID 39883 This drug requires a written request for prior authorization. All requests for Juxtapid (lomitapide) require review by a pharmacist prior
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject PCSK9 Inhibitors Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 9 References... 9 Effective Date... 01/15/2018
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationKynamro. Kynamro (mipomersen) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.02 Subject: Kynamro Page: 1 of 5 Last Review Date: September 15, 2017 Kynamro Description Kynamro
More informationHyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi
Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia
More information10/1/2008. Therapy? Disclosure Statement
What s New in Lipid Therapy? Brooke Hudspeth, PharmD Diabetes Care Kroger Pharmacy Disclosure Statement In accordance with policies set forth by the Accreditation Council for Continuing Medical Education
More informationHigh ( 50%) Restrictions mg 20-40mg Simvastatin (Zocor) 10mg 20-40mg $1.66 Pravastatin (Pravachol) mg $6.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Cholesterol P&T DATE: 5/8/2018 THERAPEUTIC CLASS: Cardiovascular REVIEW HISTORY: 5/17, 5/16, 5/15, 2/14, LOB AFFECTED: Medi-Cal
More information2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Learning Objectives
Learning Objectives Utilize evidence-based lipoprotein management strategies for non-ldl-c lipid targets Describe the risk factors, disease spectrum, and appropriate management of familial hypercholesterolemia
More informationKynamro. Kynamro (mipomersen) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.02 Subject: Kynamro Page: 1 of 5 Last Review Date: December 2, 2016 Kynamro Description Kynamro (mipomersen)
More informationMedication Policy Manual Policy No: Topic: Date of Origin: Committee Approval Date: Next Review Date: Effective Date: IMPORTANT REMINDER Description
Medication Policy Manual Policy No: dru301 Topic: Kynamro, mipomersen Date of Origin: May 16, 2013 Committee Approval Date: March 13, 2015 Next Review Date: March 2016 Effective Date: April 1, 2015 IMPORTANT
More informationLipoprotein Formation, Structure and Metabolism: Cholesterol Balance and the Regulation of Plasma Lipid Levels
Lipoprotein Formation, Structure and Metabolism: Balance and the Regulation of Plasma Lipid Levels David E. Cohen, MD, PhD Director of Hepatology, Gastroenterology Division, Brigham and Women s Hospital
More informationFamilial Hypercholesterolemia
Understanding (FH) Familial Hypercholesterolemia For more information, visit Understanding Familial Hypercholesterolemia (FH) Your doctor may have told you that too much of the bad type of cholesterol
More informationPCSK9 Inhibition: From Genetics to Patients
PCSK9 Inhibition: From Genetics to Patients John Chapman BSc, Ph.D., D.Sc., FESC Research Professor, University of Pierre and Marie Curie Director Emeritus, INSERM Dyslipidemia and Atherosclerosis Research
More informationNephrologisches Zentrum Göttingen GbR Priv. Doz. Dr. med. V. Schettler
Therapeutic algorithm for Patients with severe Hypercholesterolemia or isolated Lipoprotein(a)-Hyperlipoproteinemia with progressive cardiovascular disease: PCSK9- Inhibitors, Lipoprotein Apheresis or
More informationUPDATES IN LIPID MANAGEMENT
UPDATES IN LIPID 2017 Cardiovascular Symposium MANAGEMENT SUDHA RAVILLA, MD, DIPLOMATE, ABCL MEDICAL DIRECTOR CLINICAL LIPIDOLOGY TMHPP METABOLIC HEALTH CENTER INTRODUCTION CVD is STILL the No. 1 cause
More informationMedication Policy Manual. Topic: Juxtapid, lomitapide Date of Origin: May 16, 2013
Medication Policy Manual Policy No: dru302 Topic: Juxtapid, lomitapide Date of Origin: May 16, 2013 Committee Approval Date: March 13, 2015 Next Review Date: March 2016 Effective Date: April 1, 2015 IMPORTANT
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 8 Last Review Date: December 2, 2016 Repatha Description Repatha (evolocumab)
More informationAppendix F Simon Broome Diagnostic criteria for index individuals and relatives
Appendix F Simon Broome Diagnostic criteria for index individuals and relatives 1 SIMON BROOME DIAGNOSTIC CRITERIA FOR INDEX INDIVIDUALS (PROBANDS) 2 2 GENDER- AND AGE-SPECIFIC LDL-C CRITERIA FOR THE DIAGNOSIS
More informationAdvances in Lipid Management
Advances in Lipid Management Kavita Sharma, MD Assistant Professor of Medicine, Division of Cardiology Clinical Director of the Lipid Management Clinics, The Ohio State University Wexner Medical Center
More informationLipid metabolism in familial hypercholesterolemia
Lipid metabolism in familial hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Proprotein Convertase Subtilisin/kexin type 9 Page 1 of 24 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Proprotein Convertase Subtilisin/kexin type 9 (PCSK9)
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.16.08 Subject: Repatha Page: 1 of 8 Last Review Date: September 18, 2015 Repatha Description Repatha
More informationProprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors: PRALUENT (alirocumab) subcutaneous injection REPATHA (evolocumab) subcutaneous injection
REPATHA (evolocumab) subcutaneous injection Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationKynamro (mipomersen)
Kynamro (mipomersen) Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201803/01/2019 POLICY A. INDICATIONS The indications below including
More informationTreatment of Atherosclerosis in 2007
Treatment of Atherosclerosis in 2007 Szilard Voros, M.D. Medical Director Cardiovascular MR and CT Piedmont Hospital, Piedmont Hospital Our Paradigm Genotype Phenotype Environment Atherosclerotic Disease
More informationDrug Therapy Guidelines
Drug Therapy Guidelines PCSK9 Inhibitors: Praluent TM, Repatha TM Applicable Medical Benefit Effective: 5/1/18 Pharmacy- Formulary 1 x Next Review: 3/19 Pharmacy- Formulary 2 x Date of Origin: 10/9/15
More informationCholesterol Reduction Therapy in 2018 A Perspective Role Of Statins, Ezetimibe and PCSK9-Inhibitors
USC-April 21, 2018, Los Angeles Cholesterol Reduction Therapy in 2018 A Perspective Role Of Statins, Ezetimibe and PCSK9-Inhibitors P.K.Shah, MD, MACC Shapell and Webb Chair in Clinical Cardiology, Director,
More informationThe new guidelines issued in PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice
... PRESENTATIONS... Future Outlook: Changing Perspectives on Best Practice Based on a presentation by Daniel J. Rader, MD Presentation Summary The guidelines recently released by the National Cholesterol
More informationDyslipidemia. Team Members: Laila Mathkour, Khalid Aleedan, Bayan Al-Mugheerha, Fatima AlTassan
Dyslipidemia Objectives: Not given. Team Members: Laila Mathkour, Khalid Aleedan, Bayan Al-Mugheerha, Fatima AlTassan Team Leader: Amal Alshaibi Revised By: Yara Aldigi and Basel almeflh Resources: 435
More informationPCSK9 inhibition in homozygous familial hypercholesterolaemia
PCSK9 inhibition in homozygous familial hypercholesterolaemia Slide deck kindly supplied as an educational resource by Dr Evan A Stein MD PhD Director Emeritus Metabolic & Atherosclerosis Research Center
More informationPodcast (Video Recorded Lecture Series): Lipoprotein Metabolism and Lipid Therapy for the USMLE Step One Exam
Podcast (Video Recorded Lecture Series): Lipoprotein Metabolism and Lipid Therapy for the USMLE Step One Exam Howard J. Sachs, MD www.12daysinmarch.com Email: Howard@12daysinmarch.com Podcast (Video Recorded
More informationFamilial Hypercholesterolemia New treatments
Familial Hypercholesterolemia New treatments Prof. Shlomo Keidar Head Internal Medicine A Rambam Health Care Campus IAS, Haifa May 2013 Effect of treatment on CV survival in Familial Hypercholesterolemia
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationLipid Control Today: Management within the Context of other Cardiovascular Risk Factors
Best Practices Lipid Control Today: Management within the Context of other Cardiovascular Risk Factors James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC Lipidology & Cardiovascular Disease Prevention
More informationLIPID CLUB Rome, 2014
LIPID CLUB Rome, 2014 June the 6h 6th Hyperlipidaemia in FH Children Ornella Guardamagna University of Torino DICLOSURES Medpace Kowa DSMB member MSD, Pfizer, Synageva Investigator in industry funded trials
More information